Biodesix Inc. (BDSX) News
Filter BDSX News Items
BDSX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BDSX News From Around the Web
Below are the latest news stories about BIODESIX INC that investors may wish to consider to help them evaluate BDSX as an investment opportunity.
Zacks Industry Outlook Highlights Medpace, Doximity and BiodesixMedpace, Doximity and Biodesix have been highlighted in this Industry Outlook article. |
3 Medical Services Stocks to Buy as Industry Trends ImproveThe Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, DOCS and BDSX are set to gain the most. However, staffing shortages may disrupt the growth trend. |
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw MethodBOULDER, Colo., November 14, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient’s upper arm. |
Biodesix to Participate in Two Upcoming Investor Conferences in NovemberBOULDER, Colo., November 09, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: |
Biodesix Announces Third Quarter 2023 Results and HighlightsBOULDER, Colo., November 07, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update. |
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023BOULDER, Colo., October 24, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. |
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual MeetingBOULDER, Colo., October 03, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi. These presentations will provide new insight on the clinical utility and real-world impact of the Nodify CDT and Nodify XL2 tests in the comprehensive management of lung nodules. |
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung CancerBOULDER, Colo., September 07, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that two abstracts will be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Lung Conference on Lung Cancer (WCLC). The first presentation showcases a new analysis of the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validat |
Biodesix to Participate in Two Upcoming Investor Conferences in SeptemberBOULDER, Colo., September 05, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: |
Jack Schuler Spends US$217k On Biodesix StockPotential Biodesix, Inc. ( NASDAQ:BDSX ) shareholders may wish to note that the Independent Director, Jack Schuler... |